|Bid||0.00 x N/A|
|Ask||0.00 x N/A|
|Day's range||244.96 - 244.96|
|52-week range||244.96 - 244.96|
|Beta (5Y monthly)||0.35|
|PE ratio (TTM)||0.13|
|Earnings date||01 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Eli Lilly and Company (NYSE: LLY) today announced the upcoming retirement of one executive committee member, the naming of his successor, and the hiring of a new chief commercial officer for Loxo@Lilly.
Yahoo Finance senior columnist Rick Newman highlights the corporate backlash Indiana lawmakers are receiving after signing a new abortion ban into law.
Eli Lilly and Company (NYSE: LLY) announced today the availability of a new, citrate-free formulation of Taltz® (ixekizumab) injection 80 mg/mL. The new formulation, which was recently approved by The U.S. Food and Drug Administration in May 2022, includes the same active ingredient as the original formulation. The new Taltz formulation significantly reduced injection site pain experienced by some people immediately following injection as shown by an 86% decrease in a visual analog scale (VAS) o